Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Makoto Ueno et al.|Annals of Oncology|2019Cited by 333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 studyMakoto Ueno, Junji Furuse, Masafumi Ikeda et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 331